Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I

Journal of Nuclear Medicine

Volumn 53, Issue 7, 2012, Pages 1065-1073

  Sasaki, Takeshi ^a,b   Ito, Hiroshi ^a   Kimura, Yasuyuki ^a   Arakawa, Ryosuke ^a   Takano, Harumasa ^a   Seki, Chie ^a   Kodaka, Fumitoshi ^a   Fujie, Saori ^a   Takahata, Keisuke ^a   Nogami, Tsuyoshi ^a   Suzuki, Masayuki ^a   Fujiwara, Hironobu ^a   Takahashi, Hidehiko ^a   Nakao, Ryuji ^c   Fukumura, Toshimitsu ^a   Varrone, Andrea ^c   Halldin, Christer ^c   Nishikawa, Toru ^b   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

18F FE PE2I; Dopamine transporter; Kinetic modeling; Positron emission tomography; Radiometabolite

Indexed keywords

DOPAMINE TRANSPORTER; DRUG METABOLITE; N (3 IODOPROP 2 ENYL) 2BETA CARBOFLUOROETHOXY 3BETA (4 METHYLPHENYL)NORTROPANE F 18; RADIOLIGAND; UNCLASSIFIED DRUG;

ARTICLE; BRAIN METABOLISM; CAUDATE NUCLEUS; CEREBELLUM; COMPARTMENT MODEL; CORPUS STRIATUM; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG UPTAKE; HUMAN; HUMAN EXPERIMENT; LIGAND BINDING; MALE; MESENCEPHALON; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; RADIOACTIVITY; THALAMUS;

ADULT; ALGORITHMS; BRAIN; BRAIN CHEMISTRY; CEREBELLUM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAVENOUS; LIPIDS; MALE; MESENCEPHALON; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; YOUNG ADULT;

EID: 84863450567     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.101626     Document Type: Article

References (32)

1. Hurley MJ, Mash DC, Jenner P. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR. Eur J Neurosci. 2003;18:2668-2672. (Pubitemid 37452683)
2. Ginovart N, Lundin A, Farde L, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain. 1997;120:503-514. (Pubitemid 27153642)
3. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/ hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry. 2005;57:229-238. (Pubitemid 40187366)
4. Nakamura K, Sekine Y, Ouchi Y, et al. Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry. 2010;67:59-68.
5. 11C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res. 2009;43:1219-1223.
6. Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse. 1989;4:371-377. (Pubitemid 20044793)
7. Wong DF, Yung B, Dannals RF, et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse. 1993;15:130-142. (Pubitemid 23311584)
8. 11C] beta-CIT binding to monoamine transporters in the monkey and human brain. Synapse. 1994;16:93-103.
9. 11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. Synapse. 1994;18:152-160.
10. 127I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse. 2001;39:332-342.
11. 18F]WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects. Synapse. 1998;28:244-250.
12. Kazumata K, Dhawan V, Chaly T, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39:1521-1530. (Pubitemid 28459879)
13. Davis MR, Votaw JR, Bremner JD, et al. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med. 2003;44:855-861. (Pubitemid 39663394)
14. Emond P, Garreau L, Chalon S, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4′- iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta- (3′,4′-disubstituted phenyl)nortropane: new high-affinity and selective compounds for the dopamine transporter. J Med Chem. 1997;40:1366-1372. (Pubitemid 27198083)
15. 11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging. 2003;30:1220-1230.
16. 11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging. 2006;33:657-668.
17. 11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab. 2008;28:1059-1069.
18. 11C]PE2I and positron emission tomography: evaluation of reference tissue models. Ann Nucl Med. 2010;24:249-260.
19. Shetty HU, Zoghbi SS, Liow JS, et al. Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C] PE2I. Eur J Nucl Med Mol Imaging. 2007;34:667-678. (Pubitemid 46669359)
20. 18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse. 2009;63:871-880.
21. 18F-FEPE2I. J Nucl Med. 2011;52:132-139.
22. 18F]FE-PE2I, a new probe for the dopamine transporter. Bioorg Med Chem Lett. 2009;19:4843-4845.
23. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27: 1533-1539. (Pubitemid 47301451)
24. Leenders KL, Perani D, Lammertsma AA, et al. Cerebral blood flow, blood volume and oxygen utilization: normal values and effect of age. Brain. 1990; 113:27-47. (Pubitemid 20047108)
25. Hall H, Halldin C, Guilloteau D, et al. Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I. Neuroimage. 1999;9:108-116. (Pubitemid 29369346)
26. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
27. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716-723.
28. Carson R. Parameters estimation in positron emission tomography. In: Phelps M, Mazziotta J, Schelbert H, eds. Positron Emission Tomography Principle Applications for the Brain and the Heart. New York, NY: Raven Press; 1986:347-390.
29. 11C]MNPA: a dopamine agonist radioligand. Synapse. 2008;62:700-709.
30. Terry G, Liow JS, Chernet E, et al. Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. Neuroimage. 2008;41:690-698.
31. 11C]WAY- 100635 in humans: comparison of arterial and reference tisssue input functions. J Cereb Blood Flow Metab. 2000;20:1111-1133.
32. 18F]FE-PE2I in nonhuman primates: prediction for human studies. Nucl Med Biol. 2012;39:295-303.